News
Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback